Nε-carboxymethyl-lysine and inflammatory cytokines, markers and mediators of coronary artery disease progression in diabetes

doi:10.4239/wjd.v15.i4.575

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 4

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (472)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series.

Item

Count

PDF

WORD

HTML

363

Figures (1-1)

Sum=411

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=15

Apr 15, 2024 (publication date) through May 3, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Diabetes. Apr 15, 2024; 15(4): 575-578
Published online Apr 15, 2024. doi: 10.4239/wjd.v15.i4.575

Nε-carboxymethyl-lysine and inflammatory cytokines, markers and mediators of coronary artery disease progression in diabetes

Sonia Eiras

Sonia Eiras, Translational Cardiology, Health Research Institute, University Hospital of Santiago de Compostela, Santiago de Compostela 15706, Spain

Author contributions: Eiras S contributed to this final scientific letter.

Conflict-of-interest statement: The authors declare that they have no conflict of interest.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed by the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Sonia Eiras, BSc, Ph.D., Research Scientist, Senior Researcher, Translational Cardiology, Health Research Institute, University Hospital of Santiago de Compostela, Travesía da Choupana s/n, Santiago de Compostela 15706, Spain. sonia.eiras.penas@sergas.es

Received: November 5, 2023
Peer-review started: November 5, 2023
First decision: January 6, 2024
Revised: January 8, 2024
Accepted: March 1, 2024
Article in press: March 1, 2024
Published online: April 15, 2024

Core Tip

Core Tip: Coronary artery disease (CAD) is associated with 17.8 million deaths annually and nearly 30% have diabetes with insulin resistance. This metabolic disorder increases the circulating glucose levels that allow the non-enzymatic modifications of proteins, lipids, nucleic acids, etc. and form advanced glycation end products (AGEs). Glycosylated hemoglobin is considered a diagnostic marker for diabetes and a risk factor for CAD. However, AGEs through its receptor (RAGE) might increase signal transduction and consequently, inflammatory cytokines, and endothelial dysfunction and be markers and mediators of CAD.